References
- Salvoa EM, Samjooa IA, Tran D, et al. Letter to the Editor concerning the article: “an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy”. Expert Opin Pharmacother. 2019. DOI:10.1080/14656566.2019.1620983. [Epub ahead of print].
- Planté-Bordeneuve V, Lin H, Gollob J, et al. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy. Expert Opin Pharmacother. 2019;20(4):473–481.
- Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21.
- Coelho T, Maia LF, Martins Da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy. Neurology. 2012;79(8):785–792.
- IQWiG general methods (Version 5.0). 2017. [cited 2019 Apr 9]. Available from: https://www.iqwig.de/en/methods/methods-paper.3020.html
- NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE. 2016. [cited 2019 Apr 9]. Available from: https://scharr.dept.shef.ac.uk/nicedsu/wp-content/uploads/sites/7/2017/05/Population-adjustment-TSD-FINAL.pdf
- Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis or randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–691.
- Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: part 2. Value in health. J Int Soc Pharmacoecon Outcomes Res. 2011 Jun;14(4):429–437.
- European Medicines Agency. Orphan maintenance assessment report. Onpattro. 2018. [cited 2019 Apr 9]. Available from: https://www.ema.europa.eu/en/documents/orphan-maintenance-report/onpattro-orphan-maintenance-assessment-report_en.pdf
- TLV (Dental and Pharmaceutical Benefits Agency). Onpattro. 2018. [cited 2019 Apr 9]. Available from: https://www.tlv.se/download/18.69c4e1d51687562e1902f812/1548255242342/bes181218_underlag_onpattro.pdf